---
title: "HUAPONT LIFE SCIENCES hit the limit down, reaching a new low in over 4 months, with an annual expected loss exceeding 217 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225505151.md"
description: "HUAPONT LIFE SCIENCES hit the daily limit down, reporting a price of 3.93 yuan, creating a new low in over 4 months, with a trading volume increasing to 263 million yuan and a total market value of 7.76 billion yuan. The company announced last Friday evening that the net profit attributable to shareholders of the listed company for 2024 is expected to be a loss of 310 million to 217 million yuan, compared to a profit of 302 million yuan in the same period last year, marking a year-on-year loss. During the reporting period, the goodwill generated from the acquisition of Baisheng Pharmaceutical still showed signs of impairment. In addition, the company's agricultural chemical new materials segment is affected by industry cyclicality, with some corresponding asset groups showing signs of impairment"
datetime: "2025-01-20T05:46:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225505151.md)
  - [en](https://longbridge.com/en/news/225505151.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225505151.md)
---

# HUAPONT LIFE SCIENCES hit the limit down, reaching a new low in over 4 months, with an annual expected loss exceeding 217 million yuan

HUAPONT LIFE SCIENCES hit the limit down, reporting a price of 3.93 yuan, creating a new low in over 4 months, with a trading volume expanding to 263 million yuan and a total market value of 7.76 billion yuan. The company announced last Friday evening that the net profit attributable to shareholders of the listed company for 2024 is expected to be a loss of 310 million to 217 million yuan, compared to a profit of 302 million yuan in the same period last year, marking a year-on-year loss. During the reporting period, the goodwill generated from the acquisition of Baisheng Pharmaceutical still showed signs of impairment. In addition, the company's agricultural chemical new materials segment is affected by industry cyclicality, with some corresponding asset groups showing signs of impairment

### Related Stocks

- [002004.CN](https://longbridge.com/en/quote/002004.CN.md)
- [300758.CN](https://longbridge.com/en/quote/300758.CN.md)
- [000952.CN](https://longbridge.com/en/quote/000952.CN.md)
- [002648.CN](https://longbridge.com/en/quote/002648.CN.md)
- [300718.CN](https://longbridge.com/en/quote/300718.CN.md)
- [601137.CN](https://longbridge.com/en/quote/601137.CN.md)
- [03368.HK](https://longbridge.com/en/quote/03368.HK.md)
- [603125.CN](https://longbridge.com/en/quote/603125.CN.md)
- [00119.HK](https://longbridge.com/en/quote/00119.HK.md)
- [600346.CN](https://longbridge.com/en/quote/600346.CN.md)

## Related News & Research

- [Here's Why We're Wary Of Buying Bayer CropScience's (NSE:BAYERCROP) For Its Upcoming Dividend](https://longbridge.com/en/news/294569472.md)
- [Fresenius says FDA, EMA accept Vedolizumab biosimilar PB016 filings for review](https://longbridge.com/en/news/294463337.md)
- [11:00 ETUnderstanding Lymph System Supplements: Nation Health MD Highlights Natural Support for Everyday Lymphatic Wellness](https://longbridge.com/en/news/294585873.md)
- [11:01 ETDRYOUT® Introduces a New Category of Gear Protection with UAG Collaboration](https://longbridge.com/en/news/294385442.md)
- [New Jersey signs an 11-bill package covering transportation, healthcare, and housing](https://longbridge.com/en/news/294586504.md)